Lercanidipine in the treatment of arterial hypertension: various aspects of action in clinical practice

O.L. Rekovets


Background. One of the new third-generation calcium antagonists is lercanidipine, which, due to its high lipophilicity and vascular selectivity, can provide a gradual antihypertensive effect that lasts more than 24 hours. Materials and methods. The study included 20 patients with mild to moderate arterial hypertension (mean systolic (SBP)/diastolic blood pressure (DBP) — 149.12 ± 1.42/91.92 ± 0.93 mmHg). The criteria for inclusion in the study were: age from 18 to 75 years, mild to moderate essential hypertension. In 20 patients with mild to moderate hypertension, we studied the effect of lercanidipine at a dose of 20 mg once daily on the indicators of office blood pressure, blood pressure in daily monitoring and on central blood pressure and elastic properties of the arteries. Results. In the group of monotherapy with lercanidipine, the reduction in office SBP/DBP amounted to 12.35/8.18 mmHg (p < 0.01 for both values), heart rate increased by 4.72 bpm. In general, the target office blood pressure < 140/90 mmHg was achieved in 76.47 % of patients against the background of monotherapy with lercanidipine; in daily monitoring, blood pressure < 130/80 mmHg was achieved in 76.47 % of cases. In the group of patients treated with lercanidipine, according to ambulatory blood pressure monitoring, there was a significant decrease in the average daily SBP/DBP values by 8.65 ± 1.91/9.06 ± 2.17 mmHg, p < 0.01 for both values, and heart rate at night also significantly increased — by 5.05 ± ± 1.86 bpm, p < 0.05. The reduction in the time index for SBP and DBP for the entire period, the day period, and the reduction in the night SBP was reliable. Conclusions. According to the office measurement, treatment on the basis of lercanidipine resulted in a significant decrease in the office SBP/DBP by 12.35/8.18 mmHg. According to daily blood pressure monitoring, therapy with lercanidipine 20 mg significantly reduced daily SBP/DBP — by 8.65/9.06 mmHg, as well as central blood pressure — by 12.18 mmHg. The proportion of patients who achieved the target levels of office blood pressure and blood pressure in daily monitoring was the same — 76.47 %. There was no significant effect of lercanidipine on changes in heart rate variability. Lercanidipine administration was well tolerated by patients.


arterial hypertension; lercanidipine; treatment


Barrios V., Navarro A., Esteras A., Luque M., Romero J., Tamargo J., Prieto L., Carrasco J.L., Herranz I., Navarro-Cid J., Ruilope L.M.; Investigators of ELYPSE Study (Eficaciade Lercanidipino Perfilde Seguridad). Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y suPerfil de Seguridad // Blood Press. — 2002. — Vol. 11(2). — P. 95-100.

Borghi C. Lercanidipine in hypertension // Vasc. Health Risk Manag. — 2005. — Vol. 1(3). — P. 173-182.

Burnier M., Pruijm M., Wuerzner G. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine? // Expert Opin. Drug Metab. Toxicol. — 2009 Aug. — Vol. 5(8). — P. 981-987.

Burnier M. Renal protection with calcium antagonists: the role of lercanidipine // Curr. Med. Res Opin. — 2013 Dec. — Vol. 29(12). — P. 1727-1735.

Corsini A., Bonfatti M., Quarato P., Accomazzo M.R., Raiteri M., Sartani A., Testa R., Nicosia S., Paoletti R., Fumagalli R. Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes // J. Cardiovasc. Pharmacol. — 1996 Nov. — Vol. 28(5). — P. 687-694.

Burnier M. Renal protection with calcium antagonists: the role of lercanidipine // Curr. Med. Res Opin. — 2013 Dec. — Vol. 29(12). — P. 1727-1735.

Cesarone M.R., Incandela L., Ledda A., De Sanctis M.T., Steigerwalt R., Pellegrini L., Bucci M., Belcaro G., Ciccarelli R. Pressure and microcirculatory effects of treatment with lercanidi­pine in hypertensive patients and in vascular patients with hypertension // Angiology. — 2000 Aug. — Vol. 51 (8 Pt 2). — P. 53-63.

Corsini A., Accomazzo M.R., Canavesi M., Sartani A., Testa R., Catapano A.L., Fumagalli R., Paoletti R., Bernini F. The new calcium antagonist lercanidipine and its enantiomers affect major processes of atherogenesis in vitro: is calcium entry involved? // Blood Press. Suppl. — 1998. — Vol. 2. — P. 18-22.

Farah R., Shurtz-Swirski R., Khamisy-Farah R. Lercanidipine effect on polymorphonuclear leukocyte-related inflammation and insulin resistance in essential hypertension patients // Cardiol. Ther. — 2012 Dec. — Vol. 1(1). — P. 4.

Cicero A.F., Gerocarni B., Rosticci M., Borghi C. Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice // Clin. Exp. Hypertens. — 2012. — Vol. 34(2). — P. 113-117.

Haller H., Cosentino F., Lüscher T.F. Endothelial dysfunction, hypertension and atherosclerosis. A review of the effects of lacidipine // Drugs R.D. — 2002. — Vol. 3(5). — P. 311-323.

Herbette L.G., Vecchiarelli M., Sartani A., Leonardi A. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties // Blood Press. Suppl. — 1998. — Vol. 2. — P. 10-17.

Maксимов М.Л., Maлыхина А.И. Клиническая эффективность блокатора медленных кальциевых каналов третьего поколения лерканидипина в лечении больных артериальной гипертонией // Kaрдиология. — 2013. — Т. 53, № 6. — С. 85-90.

McClellan K.J., Jarvis B. Lercanidipine: a review of its use in hypertension // Drugs. — 2000 Nov. — Vol. 60(5). — P. 1123-1140.

Meier P., Burnier M. Lercanidipine, a third generation calcium antagonist. Which advantages? // Rev. Med. Suisse. — 2006 Sep 13. — Vol. 2(78) — P. 2047-2050, 2052-2053.

Mинушкина Л.О., Иосава И.K. Лерканидипин в лечении артериальной гипертензии // Kaрдиология. — 2012. — Т. 52, № 12. — С. 70-74.

Omboni S., Zanchetti A. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. Multicenter Study Investigators // J. Hypertens. — 1998 Dec. — Vol. 16 (12 Pt 1). — P. 1831-1838.

Sakurai-Yamashita Y., Harada N., Niwa M. Lercanidi-pine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP // Cell Mol. Neurobiol. — 2011 May. — Vol. 31(4). — P. 561-567.

Rachmani R., Levi Z., Zadok B.S., Ravid M. Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a rando-mized, prospective crossover study // Clin. Pharmacol. Ther. — 2002 Sep. — Vol. 72(3). — P . 302-307.

Yeh J.L., Hsu J.H., Liang J.C., Chen I.J., Liou S.F. Lercanidipine and labedipinedilol — A attenuate lipopolysaccharide/interferon-γ-induced inflammation in rat vascular smooth muscle cells through inhibition of HMGB1 release and MMP-2, 9 activities // Atherosclerosis. — 2013 Feb. — Vol. 226(2). — P. 364-372.

Zanchetti A., Bond M.G., Hennig M., Neiss A., Mancia G., Dal Palù C., Hansson L., Magnani B., Rahn K.H., Reid J.L., Rodicio J., Safar M., Eckes L., Rizzini P.; European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial // Circulation. — 2002 Nov 5. — Vol. 106(19). — P. 2422-2427.

Радченко Г.Д., Міхєєва К.В., Сіренко Ю.М., Кушнір С.М., Пономарьова Г.В. Ефективність лікування на основі препарату Лоріста-НД — лозартан 100 мг + гідрохлортіазид 25 мг — порівнянно з комбінацією бісопролол

мг + гідрохлортіазид 25 мг у пацієнтів з помірною та тяжкою артеріальною гіпертензією: дослідження ЕЛІЗА (результати 6-місячного спостереження) // Артеріальна гіпертензія. — 2010. — № 6. — С. 23-35.

Karaca I., Coşkun N., Yavuzkir M., Ilkay E., Dağli N., Işik A., Balin M., Akbulut M., Arslan N. Effect of diltiazem and metoprolol on left atrial appendix functions in patients with nonvalvular chronic atrial fibrillation // Anadolu Kardiyol. Derg. — 2007 Mar. — Vol. 7(1). — P. 37-41.

Kawano Y., Makino Y., Okuda N., Takishita S., Omae T. Effects of diltiazem retard on ambulatory blood pressure and heart rate variability in patients with essential hypertension // Blood Press. Monit. — 2000 Jun. — Vol. 5(3). — P. 181-185.

Luk J.H., Walsh B., Yasbin P. Safety and efficacy of prehospital diltiazem // West J. Emerg. Med. — 2013 May. — Vol. 14(3). — P. 296-300.

Mackenzie I.S., McEniery C.M., Dhakam Z., Brown M.J., Cockcroft J.R., Wilkinson I.B. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension // Hypertension. — 2009 — Vol. 54(2). — P. 409-413.

Bevan R.D., Bevan J.A., Frazee J.G. Diltiazem protects against functional changes in chronic cerebrovasospasm in monkeys // Stroke. — 1988 Jan. — Vol. 19(1). — P. 73-79.

Wright J.T. Jr, Sica D.A., Gana T.J., Bohannon K., Pascual L.G., Albert K.S. Antihypertensive efficacy of night-time graded-release diltiazem versus morning amlodipine in African Americans // Am. J. Hypertens. — 2004 Sep. — Vol. 17(9). — P. 734-742.

Yano M., Kumada T., Matsuzaki M., Kohno M., Hiro T.,

Kohtoku S., Miura T., Katayama K., Ozaki M., Kusukawa R. Effect of diltiazem on aortic pressure-diameter relationship in dogs // Am. J. Physiol. — 1989 Jun. — Vol. 256 (6 Pt 2). — P. 1580-1587.

Watts R.W., Wing L.M. A placebo-controlled comparison of diltiazem and amlodipine monotherapy in essential hypertension using 24-h ambulatory monitoring // Blood Press. — 1998 Jan. — Vol. 7(1). — P. 25-30.

Whelton A., Eff J., Magner D.J. Sustained antihypertensive activity of diltiazem SR: double-blind, placebo-controlled study with 24-hour ambulatory blood pressure monitoring //

J. Clin. Pharmacol. — 1992 Sep. — Vol. 32(9). — P. 808-815.

Pool P.E., Massie B.M., Venkataraman K., Hirsch A.T., Samant D.R., Seagren S.C., Gaw J., Salel A.F., Tubau J.F. Diltiazem as monotherapy for systemic hypertension: a multicenter, randomized, placebo-controlled trial // Am. J. Cardiol. — 1986 Feb 1. — Vol. 57(4). — P. 212-217.

Barner H.B., Jellinek M., Standeven J.W., Menz L.J., Hahn J.W. Cold blood-diltiazem cardioplegia // Ann. Thorac. Surg. — 1982 Jan. — Vol. 33(1). — P. 55-63.

Chrysant S.G., Miller E. Effects of atenolol and diltiazem-SR on exercise and pressure load in hypertensive patients // Clin. Cardiol. — 1994 Dec. — Vol. 17(12). — P. 670-674.

Betocchi S., Piscione F., Losi M.A., Pace L., Boccalatte M., Perrone-Filardi P., Cappelli-Bigazzi, Briguori C., Manganelli F., Ciampi Q., Salvatore M., Chiariello M. Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy // Am. J. Cardiol. — 1996 Aug 15. — Vol. 78(4). — P. 451-457.

Chern M.S., Lin F.C., Wu D. Comparison of clinical efficacy and adverse effects between extended-release felodipine and slow-release diltiazem in patients with isolated systolic hypertension // Changgeng Yi Xue Za Zhi. — 1999 Mar. — Vol. 22(1). — P. 44-51.

Cholley B.P., Lang R.M., Korcarz C.E., Shroff S.G. Smooth muscle relaxation and local hydraulic impedance properties of the aorta // J. Appl. Physiol. — 2001 Jun. — Vol. 90(6). — P. 2427-2438.

Coca A., Sobrino J., Soler J., Módol J., Palos M.A., Mínguez A., Esqúe J., Plana J., Cases M., Closas J., de la Sierra A. Trough-to-peak ratio and circadian blood pressure profile after treatment with once-daily extended-release diltiazem, 240 mg, in patients with mild-to-moderate essential hypertension // J. Cardiovasc. Pharmacol. — 1997 Mar. — Vol. 29(3). — P. 316-322.

Хвороби системи кровообігу як медико-соціальна і суспільно-політична проблема: Аналітично-статистич. посібник / Під ред. В.М. Коваленка, В.М. Корнацького. — К., 2014. — С. 115.

2007 European Society of Hypertension — European Society of Cardiology guidelines for management of arterial hypertension // J. Hypertension. — 2007. — Vol. 25. — P. 1105-1187.

Raicu M., Pojoga L., Simionescu N., Simionescu M. Differential effect of two calcium channel blockers nifedipine and diltiazem on atherogenesis in hypercholesterolemic hamster // J. Submicrosc. Cytol. Pathol. — 1996 Apr. — Vol. 28(2). — P. 265-275.

Raicu M., Pojoga L., Simionescu N., Simionescu M. The effect of ACE inhibitors on atheroma formation is potentiated by association with a calcium channel blocker. A biochemical and ultrastructural study // J. Submicrosc. Cytol. Pathol. — 1997 Jul. — Vol. 29(3). — P. 317-328.

Richard S. Vascular effects of calcium channel antagonists: new evidence // Drugs. — 2005. — Vol. 65(2). — P. 1-10.

Sakurai-Yamashita Y., Harada N., Niwa M. Lercanidipine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP // Cell Mol. Neurobiol. — 2011 May. — Vol. 31(4). — P. 561-567.

Scholze J.E. Differential therapy with calcium antagonists // Herz. — 2003 Dec. — Vol. 28(8). — P. 754-763.

De Ciuceis C., Salvetti M., Rossini C., Muiesan M.L., Pai-ni A., Duse S., La Boria E., Semeraro F., Cancarini A., Rosei C.A., Sarkar A., Ruggeri G., Caimi L., Ricotta D., Rizzoni D., Rosei E.A. Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension // J. Hypertens. — 2014 Mar. — Vol. 32(3). — P. 565-574.

Horwitz L.D., Weinberger H.D., Clegg L. Comparison of amlodipine and long-acting diltiazem in the treatment of mild or moderate hypertension // Am. J. Hypertens. — 1997 Nov. — Vol. 10(11). — P. 1263-1269.

Mackenzie I.S., McEniery C.M., Dhakam Z., Brown M.J., Cockcroft J.R., Wilkinson I.B. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension // Hypertension. — 2009 Aug. — Vol. 54(2). — P. 409-413.

Nayler W.G. Review of preclinical data of calcium channel blockers and atherosclerosis // J. Cardiovasc. Pharmacol. — 1999. — Vol. 33 (Suppl 2). — P. 7-11.

Paoletti R., Bernini F., Corsini A., Soma M.R. The antiatherosclerotic effects of calcium antagonists // J. Cardiovasc. Pharmacol. — 1995. — Vol. 3. — P. 6-10.

Woźnicka-Leśkiewicz L., Posadzy-Małaczyńska A., Juszkat R. The impact of ankle brachial index and pulse wave velocity on cardiovascular risk according to SCORE and Framingham scales and sex differences // J. Hum. Hypertens. — 2014 Sep. — 25. doi: 10.1038/jhh.2014.80 [Epub ahead of print].

Wright J.T. Jr, Sica D.A., Gana T.J., Bohannon K., Pascual L.G., Albert K.S. Antihypertensive efficacy of night-time graded-release diltiazem versus morning amlodipine in African Americans // Am. J. Hypertens. — 2004 Sep. — Vol. 17(9). — P. 734-742.

Williams B., Lacy P., Cruickshank J. et al. Impact of Statin Therapy on Central Aortic Pressures and Hemodynamics Principal Results of the Conduit Artery Function Evaluation-Li-pid-Lowering Arm (CAFE-LLA) Study // Circulation. — 2009. — Vol. 119. — P. 53-61.

Asmar R. Effect of antihypertensive agents on arterial stiffness as evaluated by pulse wave velocity: clinical implications // Am. J. Cardiovasc. Drugs. — 2001. — Vol. 1(5). — P. 387-397.

Mackenzie I.S., McEniery C.M., Dhakam Z., Brown M.J., Cockcroft J.R., Wilkinson I.B. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension // Hypertension. — 2009 — Vol. 54(2). — P. 409-413.

Protogerou A., Blacher J., Stergiou G.S., Achimastos A., Safar M.E. Blood pressure response under chronic antihypertensive drug therapy: the role of aortic stiffness in the REASON (Preterax in Regression of Arterial Stiffness in a Controlled Double-Blind) study // J. Am. Coll. Cardiol. — 2009 Feb 3. — Vol. 53(5). — P. 445-451.

Triantafyllidi H., Trivilou P., Ikonomidis I., Kontsas K., Tzortzis S., Pavlidis G., Lekakis J. Is Arterial Hypertension Control Enough to Improve Aortic Stiffness in Untreated Patients With Hypertension? A 3-Year Follow-Up Study // Angiology. — 2014 Sep 30. pii: 0003319714552811 [Epub ahead of print].

Vayssettes-Courchay C., Ragonnet C., Isabelle M., Verbeuren T.J. Aortic stiffness in vivo in hypertensive rat via echo-tracking: analysis of the pulsatile distension waveform // Am. J. Physiol. Heart Circ. Physiol. — 2011 Aug. — Vol. 301(2). — P. 382-390.

Hulley S.B., Furberg C.D., Gurland B., McDonald R., Perry H.M., Schnaper H.W., Schoenberger J.A., Smith W.M., Vogt T.M.; Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone // Am. J. Cardiol. — 1985 Dec. — Vol. 56(15). — P. 913-920.

Lindsay R.S., Resnick H.E., Zhu J., Tun M.L., Ho-ward B.V., Zhang Y., Yeh J., Best L.G.; Adiponectin and coronary heart disease: the Strong Heart Study // Arterioscler. Thromb. Vasc. Biol. — 2005 Mar. — Vol. 25(3). — P. 15-16.

Safar M., Protogerou A., Blacher J. Central blood pressure under angiotensin and calcium channel blockade // Hypertension. — 2009. — Vol. 54. — P. 704-706.

Fumiharu Togo, Masaya Takahashi. Heart Rate Variability in Occupational Health — A Systematic Review // Industrial Health. — 2009. — Vol. 47. — P. 589-602.

Piccirillo G., Fimognari F.L., Munizzi M.R., Bucca C., Cacciafesta M., Marigliano V. Age-depended influence on heart rate variability in salt-sensitive hypertensive subjects // J. Am. Geriatr. Soc. — 1996 May. — Vol. 44(5). — P. 530-538.

Salo T.M., Viikari J.S., Antila K.J., Voipio-Pulkki L.M., Jalonen J.O., Valimaki I.A. Antihypertensive treatment and hert rate variability in diabetic patients: role of cardiac autonomic neuropathy // J. Auton. Nerv. Syst. — 1996 Aug 27. —

Vol. 60 (1–2). — P. 61-70.

Wang H.B., Shi Q., Zhang C. Effects of heart rate variability and smoothness index on reversal of hypertensive left ventricular hypertrophy // Zhonghua Yi Xue Za Zhi. — 2011 Mar 29. — Vol. 91(12). — P. 832-835.

Lotufo P.A., Valiengo L., Bensenor I.M., Brunoni A.R. A systematic review and meta-analysis of heart rate variability in epilepsy and antiepileptic drugs // Epilepsia. — 2012 Feb. — Vol. 53(2). — P. 272-282.

Li L.X., Tang W., Chen B.J., Wang T. Cross-sectional study of relation between blood pressure and heart rate variability in patients with peritoneal dialysis // Beijing Da Xue Xue Bao. — 2011 Dec 18. — Vol. 43(6). — P. 849-854.

Weston K.S., Sacre J.W., Jellis C.L., Coombes J.S. Contribution of autonomic dysfunction to abnormal exercise blood pressure in type 2 diabetes mellitus // J. Sci Med. Sport. — 2012 May 15 [Epub ahead of print].

Zhou Y., Xie G., Wang J., Yang S. Cardiovascular Risc Factors Significantly Correlate With Automatic Nervous System Activity in Children // Can J. Cardiol. — 2012 May 3 [Epub ahead of print].

Evrengul H., Tanriverdi H., Kose S., Amasyali B., Ki-lic A., Celik T., Turhan H. The relationship between heart rate recovery and heart rate variability in coronary artery disease // Ann. Noninvasive Electrocardiol. — 2006 Apr. — Vol. 11(2). — P. 154-162.

Eryonucu B., Bilge M., Guler N., Uygan I. The effect of autonomic nervous system activity on exaggerated blood pressure response to exercise: evaluation by heart rate variability // Acta Cardiol. — 2000 Jun. — Vol. 55(3). — P. 181-185.

Piccrillo G., Elvira S., Viola E., Bucca C., Durante M., Raganto P., Marigliano V. Automatic modulation of heart rate and blood pressure in hypertensive subjects with symptoms of anxiety // Clin. Sci (Lond). — 1998 Jul. — Vol. 95(1). — P. 43-52.

Piccrillo G., Vetta F., Viola E., Santagada E., Ronzoni S., Cacciafesta M., Marigliano V. Heart rate and blood pressure variability in obese normotensive subjects // Int. J. Obes. Relat. Metab. Disord. — 1998 Aug. — Vol. 22(8). — P. 741-750.

Piccrillo G., Munizzi M.R., Fimognari F.L., Marigliano V. Heart rate variability in hypertensive subjects // Int. J. Cardiol. — 1996 Mar. — Vol. 53(3). — P. 291-298.

Valera B., Dewailly E., Poirier P.P., Counil E., Suhas E. Influence of mercury exposure on blood pressure, resting heart rate and heart rate variability in French Polynesians: a cross-sectional study // Envaironmental Health. — 2011. — Vol. 10. — P. 99.

Tsuji H., Venditti Jr, Manders E.S., Evans J.C., Larson M.J., Feldman C.L., Levy D. Reduced heart rate variability and mortality risk in elderly cohort. The Framingham // Circulation. — 1994. — Vol. 90. — P. 878-883.

Singh J.P., Larson M.G., Tsuji H., Evans J.C., O’Donnell C.J., Levy D. Reduced Heart Rate Variability and New-Onset Hypertension // Hypertension. — 1998. — Vol. 32. — P. 293-297.

Gyung-Mee Kim, Jong-Min Woo. Determination for Heart Rate Variability in a Normal Korean Population // J. Korean Med. Sci. — 2011 Oct. — Vol. 26(10). — P. 1293-1298.

Kinoshita H., Kuwahara K., Takano M., Arai Y., Kuwabara Y., Yasuno S. et al. T-Type Ca2+ Channel Blockade Prevents Sudden Death in Mice With Heart Failure // Circulation. — 2009. — Vol. 120. — P. 743-752.

Dahlof B., Devereux R.B., Kjeldsen S.E. et al. LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol // Lancet. — 2002. — Vol. 359. — P. 995-1003.

Blacher J., Asmar R., Djane S., London G.M., Safar M.E. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients // Hypertension. — 1999. — Vol. 33. — P. 1111-1117.

Blacher J., Guerin A.P., Pannier B. et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease // Hypertension. — 2001. — Vol. 38. — P. 938-942.

Sutton-Tyrrell K., Mackey R.H., Holubkov R. et al. Measurement variation of aortic pulse wave velo-

city in the elderly // Am. J. Hypertens. — 2001. — Vol. 14. — P. 463-468.

Blacher J., Pannier B., Guerin A.P. et al. Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease // Hypertension. — 1998. — Vol. 32. — P. 570-574.

Boutouyrie P., Achouba A., Trunet P. et al. for the EXPLOR Trialist Group. Amlodipine-Valsartan Combination Decreases Central Systolic Blood Pressure More Effectively Than the Amlodipine-Atenolol Combination The EXPLOR Study // Hypertension. — 2010. — Vol. 55. — P. 1314-1322.

Cohn J. Is it the blood pressure or the blood vessel? // Journal of American Society of Hypertension. — 2007. — Vol. 1. — P. 5-16.

Matsui Y., Eguchi K., O’Rourke M. et al. Differential Effects Between a Calcium Channel Blocker and a Diuretic When Used in Combination With Angiotensin II Receptor Blocker on Central Aortic Pressure in Hypertensive Patients // Hypertension. — 2009. — Vol. 54. — P. 716-723.

Copyright (c) 2018 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2018


   Seo анализ сайта